GSK confirms job cuts but avoids specifics
February 5, 2010Research and Development, Sales and Marketing 2009 financials, GlaxoSmithKline
GlaxoSmithKline has sidestepped questions about the internal fall-out from its new plan to slash R&D infrastructure costs. Presenting the company’s …
Miguel Forte joins TxCell
February 5, 2010Research and Development TxCell, appointment, research and development
French biotech TxCell has appointed Miguel Forte to fill its newly-created role of chief medical officer. Miguel joins the company …
Portfolio Harmony in five easy steps
February 5, 2010Sales and Marketing product portfolio
Portfolio planning should be a practical process that delivers a programme of work to take you to sunnier shores. All …
Zeftera problems weigh down Basilea
February 5, 2010Sales and Marketing 2009 financials, Basilea, Zeftera
Specialist Swiss pharma company Basilea has announced a doubling of its revenues in 2009, thanks to the launch of its …
GSK acquires respiratory candidate
February 4, 2010Research and Development Apeiron, GlaxoSmithKline, respiratory
GlaxoSmithKline has acquired exclusive rights to a biotherapeutic enzyme developed for use against Acute Respiratory Distress Syndrome (ARDS). The move …
Wyeth acquisition yet to shake Pfizer’s Lipitor dependence
February 4, 2010Sales and Marketing 2009 financials, Lipitor, Pfizer
Pfizer’s profits rose by 7% last year on the back of a 4% increase in revenue driven by cholesterol treatment …
Fishawack makes US acquisition
February 4, 2010Medical Communications Nexus Communications, fishawack
Cheshire-based healthcare agency Fishawack Communications has bought US outfit Nexus Communications. The company says this acquisition is part of a …
Oxford Immunotec appoints Frank Vandeputte
February 4, 2010Sales and Marketing Oxford Immunotec, appointment, medical devices, sales and marketing
Medical diagnostics company Oxford Immunotec has appointed Frank Vandeputte vice president, sales and marketing. He was formerly VP, Europe for …
Eden Biodesign passes into Watson Pharma’s hands
February 4, 2010Manufacturing and Production Eden Biodesign, Watson Pharma, biologicals
UK biologics manufacturing specialist Eden Biodesign has been bought by US drugmaker Watson Pharmaceuticals in a $15 million deal. The …
Lancet retracts MMR research conclusions
February 3, 2010Research and Development MMR, Sanofi, vaccines
The Lancet, the journal which originally published the controversial research linking the MMR vaccine to autism has issued a full …
Digital Pharma: New EMA website previewed
February 3, 2010Research and Development, Sales and Marketing EMA, branding, digital pharma
The European Medicines Agency is preparing to overhaul its website to make it easier for users to get information. This …
Digital added to PM’s as Langland clean up
February 3, 2010Medical Communications Langland, awards, pm society
Langland swept the board at the PM Society’s Advertising Awards on 29 January with seven wins across 20 award categories. …
FDA to assess Neupogen biosimilar
February 3, 2010Research and Development, Sales and Marketing Hospira, Teva, biosimilars
US regulator the FDA has agreed to assess Teva’s application for a biosimilar version of Amgen’s Neupogen (filgrastim). XM02, a …
Genentech integration hits Roche profits
February 3, 2010Sales and Marketing 2009 financials, Genentech, Roche
Roche achieved healthy sales growth in 2009 but saw a 22% drop in net income due to the cost gaining …
Talking Careers: The brief has changed
February 2, 2010Business Services Talking Point, interim management, rsa, talking careers
Planning for the future is crucial at any time, but particularly when the market has changed and contracted as the …
Brennan maintains support for US reforms
February 2, 2010Sales and Marketing Obama, US healthcare
David Brennan has reiterated the industry’s early support for President Obama’s healthcare plans, but acknowledged the recent election of a …
Parexel sees signs of recovery in Q2 figures
February 2, 2010Research and Development CRO, Parexel
Contract research organisation Parexel International’s second-quarter net profit fell 34% to $3.5 million on restructuring and investment-impairment charges, but still …
Novo buoyed by insulin portfolio
February 2, 2010Sales and Marketing 2009 financials, Novo Nordisk, Victoza
Danish pharma company Novo Nordisk managed a double-digit rise in sales and profits in 2009, buoyed by insulin products NovoRapid, …
Job cuts at GlaxoSmithKline and AstraZeneca
February 2, 2010Research and Development, Sales and Marketing AstraZeneca, GlaxoSmithKline
Britain’s two biggest pharma companies GlaxoSmithKline and AstraZeneca are poised to make deep job cuts as business models continue to …
Servier fails to overturn NICE osteoporotic guidance
February 2, 2010Sales and Marketing NICE, Servier, osteoporosis
Servier’s challenge to NICE guidance on preventing osteoporotic fractures has proved unsuccessful, with the watchdog’s original decision still standing. This …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
